Diclofenac-13C6 (sodium)

Diclofenac-13C6 (Sodium) is the 13C6 labeled Diclofenac (Sodium) . Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade.

Product Specifications

CAS Number

[1261393-73-0]

Product Name Alternative

GP 45840-13C6

UNSPSC

12352005

Hazard Statement

H301, H410

Target

Apoptosis; COX; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Immunology/Inflammation; Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/diclofenac-13c6-sodium.html

Purity

99.96

Solubility

10 mM in DMSO

Smiles

O=C(O[Na])C[13C]([13CH]=[13CH][13CH]=[13CH]1)=[13C]1NC2=C(C=CC=C2Cl)Cl

Molecular Formula

C8 13C6H10Cl2NNaO2

Molecular Weight

324.09

Precautions

H301, H410

References & Citations

[1]Chiho Kudo, et al. Diclofenac Inhibits Proliferation and Differentiation of Neural Stem Cells. Biochem Pharmacol. 2003 Jul 15;66 (2) :289-95.|[2]Labib MB, et al. Design, synthesis of novel isoindoline hybrids as COX-2 inhibitors: Anti-inflammatory, analgesic activities and docking study. Bioorg Chem. 2018 Oct;80:70-80.|[3]Riendeau D, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121 (1) :105-17.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.